Protagonist Therapeutics, Inc. (PTGX) Q1 2018 Earnings Results

Protagonist Therapeutics Misses on EPS, Stock Up 1.57%

The earnings report reflects ongoing challenges for Protagonist Therapeutics, particularly with EPS falling short of expectations. Despite this, the stock rose by 1.57%, likely driven by investor optimism about the company's clinical development efforts. The lack of revenue data and guidance suggests uncertainty in the near term, but the market seems to remain hopeful about future advancements.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.36	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Neutral

Management emphasized the importance of ongoing clinical trials. There was no specific guidance provided for future earnings or revenue.

Management did not provide specific revenue guidance for the upcoming quarters.

The focus remains on advancing clinical trials and product development.

Protagonist Therapeutics Misses on EPS, Stock Up 1.57%

Key numbers

Management commentary

Protagonist Therapeutics, Inc.

More earnings this week

Protagonist Therapeutics Misses on EPS, Stock Up 1.57%

Key numbers

Management commentary